NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, inclusive (the “Class Period”), of the important May 20, 2025 lead plaintiff deadline. SO WHAT: If you purchased Sana securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO ...

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024. Follow the link below to get more information and be contacted by a member of our team: https:// ...

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. (“Sana” or the “Company”) (NASDAQ: SANA) and certain officers.  The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and Novemb ...

Core Viewpoint - A class action securities lawsuit has been filed against Sana Biotechnology, Inc. due to alleged securities fraud affecting investors between March 17, 2023, and November 4, 2024 [1][2]. Group 1: Allegations and Financial Concerns - The lawsuit claims that Sana was at significant risk of having insufficient funds to maintain its operations and advance its product candidates [2]. - It is alleged that product candidates SC291 in oncology, SC379, and SG299 were less promising than previously communicated to investors [2]. - To preserve cash and focus on more promising candidates, Sana was likely to decrease funding for or discontinue SC291, SC379, and SG299, as well as significantly reduce its workforce [2]. - The defendants are accused of overstating Sana's financial capacity to maintain operations and advance existing product candidates, leading to materially false and misleading public statements [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the relevant timeframe have until May 20, 2025, to request to be appointed as lead plaintiff, although participation does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against Sana Biotechnology, Inc. alleging securities fraud that affected investors between March 17, 2023, and November 4, 2024 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Sana Biotechnology was at significant risk of having insufficient funds to maintain its operations and advance its product candidates [2]. - It is alleged that the product candidates SC291 in oncology, SC379, and SG299 were less promising than previously communicated to investors [2]. - The complaint suggests that to preserve cash and focus on more promising candidates, Sana was likely to decrease funding for or discontinue SC291, SC379, and SG299, and significantly reduce its workforce [2]. - As a result, the defendants are accused of overstating Sana's financial capacity to maintain operations and advance its product candidates, leading to materially false and misleading public statements [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until May 20, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the United States [4].

NEW YORK, April 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/sana-biotechnology-inc-loss-submission-form/?id=143343&from=4 CLASS PERIOD: Mar ...

Core Viewpoint - A class action has been initiated against Sana Biotechnology, Inc. for allegedly misleading investors regarding its financial stability and product development during the specified Class Period from March 17, 2023, to November 4, 2024 [1][3]. Group 1: Class Action Details - Investors who purchased securities during the Class Period can file a lead plaintiff motion by May 20, 2025 [1]. - The Portnoy Law Firm is offering complimentary case evaluations to affected investors [2]. Group 2: Allegations Against the Company - The complaint claims that Sana was at significant risk of lacking sufficient capital to sustain operations and product development [3]. - It is alleged that the Company's product programs, including SC291 in oncology, SC379, and SG299, were less promising than represented [3]. - The complaint suggests that Sana may reduce funding for or discontinue certain product candidates and significantly cut its workforce to conserve cash [3]. - As a result, the public statements made by the Company were materially false and misleading throughout the Class Period [3].

NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, inclusive (the "Class Period"), of the important May 20, 2025 lead plaintiff deadline. Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www ...

Core Viewpoint - The article discusses the investigation into Sana Biotechnology, Inc. for potential securities law violations, highlighting significant financial risks and operational changes that have impacted the company's stock performance. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is investigating potential claims against Sana Biotechnology, reminding investors of the May 20, 2025 deadline to seek lead plaintiff status in a federal securities class action [2] - The complaint alleges that Sana and its executives made false or misleading statements regarding the company's financial health and product development [4] Group 2: Financial Performance and Operational Changes - On October 10, 2023, Sana announced a reduction in near-term spending on its fusogen platform and a 29% headcount reduction, aiming to keep its 2024 operating cash burn below $200 million [5][6] - Following this announcement, Sana's stock price fell by $0.34 per share, or 8.95%, closing at $3.46 per share [6] - On November 4, 2024, Sana announced the suspension of development for SC291 and SC379, reallocating resources to its type 1 diabetes program, which extended its cash runway into 2026 [7] - This announcement led to a further decline in stock price by $0.37 per share, or 9.84%, closing at $3.39 per share [7]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Sana Biotechnology, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on May 20, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Sana securities between March 17, 2023, and November 4, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by May 20, 2025 [2]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, Sana made false and misleading statements regarding its financial stability and the potential of its product candidates, including SC291, SC379, and SG299 [4]. - It is claimed that Sana was at significant risk of insufficient funds to maintain operations and that the company was likely to decrease funding for certain product candidates and reduce its workforce [4].